A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
Hiddo J.L. Heerspink(University Medical Center Groningen), Lesley A. Inker(Tufts Medical Center), Thierry Hannedouche, Willem Collier(University of Utah), Brendon L. Neuen(The George Institute for Global Health), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), Vlado Perkovic(New South Wales Department of Health), Christoph Wanner(Universitätsklinikum Würzburg), Fernando Caravaca‐Fontán(Universidad Complutense de Madrid), Julia B. Lewis, Hocine Tighiouart(Tufts University), Francesco Locatelli(University of Modena and Reggio Emilia), Enyu Imai(Takara (Japan)), Juhi Chaudhari(Tufts Medical Center), Bart Maes(AZ Delta), Ronald D. Perrone(Tufts Medical Center), Tazeen H. Jafar(Apple (Israel)), Francesco Paolo Schena(University of Bari Aldo Moro), Tom Greene(University of Utah), Shiyuan Miao(Tufts Medical Center), Jürgen Floege(RWTH Aachen University), Gerald B. Appel(Columbia University Irving Medical Center), Philip Kam‐Tao Li(Hospital Authority)
Cited by 19
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k